Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis

Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from LGTB-neisseria meningitidis

US Patent 8221770 · Granted Jul 17, 2012

Estimated economic value: $16,069,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Multivalent vaccine compositions and uses thereof2025
Methods of producing bioconjugates of E. coli O-antigen polysaccharides, composi2025
Immunogenic composition2024
Methods and compositions for immune protection against extra-intestinal pathogen2024
Immunogenic composition2024
Bioconjugates of E. coli O-antigen polysaccharides, methods of production thereo2024
Vaccine2023
Methods of boosting immune responses2023
Methods of producing bioconjugates of E. coli o-antigen polysaccharides, composi2022
Methods and compositions for immune protection against extra-intestinal pathogen2022
Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereo2022
Immunogenic composition comprising staphylococcal antigens2022